sona health, for all

🩻 A novel ultrasound technology is being utilised to accurately measure and monitor breast density, and in the process improve early detection rates and assess how at risk individual women might be from developing the disease. Approximately 70% of breast cancers are detected in women with dense breasts, however, most women do not know their breast density. Nearly half of women have high breast density and high breast density both increases breast cancer risk (by up to a factor of six) and causes cancers to be missed on screening mammograms. Sona's technology enables women to proactively monitor their breast health before they are old enough to access a mammogram. Unlike traditional X-Ray-based methods, which pose risks due to radiation exposure, sona’s approach uses innovative ultrasound sensor technology to provide safer, more sensitive breast density assessments for women of all ages without the need for imaging or radiologists. 💬 Daniel Sarno, National Physical Laboratory (NPL) senior scientist and sona health, for all CTO, said: “Our mission at sona is to provide women with an earlier, safer, and more accessible way to monitor their breast health. We want to bring our groundbreaking ultrasound-based technology to clinics and communities and ensure that breast density detection is no longer limited by age or access to traditional mammograms. “By expanding early breast cancer risk assessment capabilities across socioeconomic boundaries, sona’s approach contributes to the UK’s objectives of reducing health inequalities by making healthcare more accessible to all women, regardless of background or location. “We believe our innovative technology will create a new standard for women to take control of their breast health in a way that’s never been possible before.” Read more: https://lnkd.in/e4eAfMtV

Happy to share the first in a series of White Papers addressing challenges and opportunities within breast screening for the UK. This first White Paper provides an overview of some of the key topics being discussed to modernise pathways to seek better clinical outcomes as well as addressing workforce pressures. In it we look at: 1) The option to extend the age range for screening in light of increasing cases being detected in younger women. 2) Utilising risk factors to target those who need screening most 3) Technology adoption to increase cancer detection rates 4) Utilising AI to help build capacity in the system Future reports will delve into more detail on some of these key topics. #breastcancer #cancer #preventativecare #womenshealth Hologic, Inc. Anna Hagen Sue Branfield

We are proud to be working in partnership with UK Innovation & Science Seed Fund to support Sona from National Physical Laboratory (NPL) and its innovative solution. Unlike traditional methods that pose risks due to radiation exposure, Sona leverages ultrasound technology to provide safer breast density assessments. This is one example of how we’re accelerating government innovations towards the market, to impact growth.

Women with ‘significantly denser’ breast tissue are around 6 times more likely to develop breast cancer than those with ‘low breast density’. Sona is a small device developed by National Physical Laboratory (NPL) with ultrasound-based breast density assessment technologies to detect the risk of breast cancer. GOTT is supporting Department for Science, Innovation and Technology to drive innovations that have the potential to change lives, benefit the NHS and generate economic growth. Watch the video to learn more about why GOTT is funding Sona.

📣 News 📣 First investment of £200k into Sona from the UK Innovation & Science Seed Fund (UKI2S), managed by Future Planet Capital, paves the way for spinout formation in 2025 in addition to £250K in grant funding for advanced product development from the Government Office for Technology Transfer. Sona’s mission is to transform breast cancer screening, creating a new standard for breast density assessment and monitoring, offering safer and more accessible breast health information for women of all ages. With its compact form, Sona’s simple, low-cost device is positioned for deployment in medical practices, local health clinics and primary care sites, expanding early breast cancer risk assessment capabilities across socioeconomic boundaries. This approach contributes to the UK’s objectives of reducing health inequalities by making healthcare more accessible to all women, regardless of background or location. https://lnkd.in/ercyaHWn

📣 We are pleased to announce that we are funding Sona, a pioneering device from National Physical Laboratory (NPL) that detects breast density alongside investment from UK Innovation & Science Seed Fund. GOTT’s funding will allow the patented Sona solution to advance its development and help provide women with a safer, earlier, and more accessible way to monitor their breast health. #spinout #innovation

Happy to share the first in a series of White Papers addressing challenges and opportunities within breast screening for the UK. This first White Paper provides an overview of some of the key topics being discussed to modernise pathways to seek better clinical outcomes as well as addressing workforce pressures. In it we look at: 1) The option to extend the age range for screening in light of increasing cases being detected in younger women. 2) Utilising risk factors to target those who need screening most 3) Technology adoption to increase cancer detection rates 4) Utilising AI to help build capacity in the system Future reports will delve into more detail on some of these key topics. #breastcancer #cancer #preventativecare #womenshealth Hologic, Inc. Anna Hagen Sue Branfield